Recent Headlines
A system of pooled coronavirus tests to catch asymptomatic infections among Duke University students helped keep the campus open in the midst of the pandemic.
-
The World Health Organization guidelines panel advised against using the antiviral remdesivir for hospitalized patients.
-
Amid pandemic fatigue, people are questioning the new California COVID-19 lockdown measures. Experts say these rules could help slow the infection rate.
-
Major movie theater chains have responded to the pandemic by putting COVID-19 protocols in place. Public health experts assess the risks.
AstraZeneca and Oxford University say their COVID-19 vaccine is up to 90% effective in preventing the disease in late-stage trials.
The coronavirus is infecting more Californians daily than at any other point in the COVID-19 pandemic, raising concerns about a peak in deaths by Christmas.
COVID-19 spread hits unprecedented levels in California and officials worry how bad it will get
Los Angeles County reported nearly 5,000 new coronavirus cases Thursday, the highest single-day count so far. A look at what could be next.
A clinical trial of the coronavirus-fighting ability of face masks had inconclusive results, but researchers say it strengthens the case for universal mask use.
Pfizer has asked the FDA to allow emergency use of its COVID-19 vaccine, which could the bring the first shots as early as next month.
The Arecibo Observatory telescope in Puerto Rico will close, a blow to scientists worldwide who depend on it to search for planets, asteroids and extraterrestrial life.
After previously declining to issue firm guidance for holiday gatherings, the CDC recommends that Americans just stay home this Thanksgiving.
Health news, ideas, advice and commentary.
Most Read
-
A system of pooled coronavirus tests to catch asymptomatic infections among Duke University students helped keep the campus open in the midst of the pandemic.
-
Can you have Thanksgiving during the COVID-19 pandemic? Researchers have created an interactive map that estimates the risk you’ll face in any county.
-
A coronavirus outbreak tied to a wedding reception caused 177 infections and 7 COVID-19 deaths. It shows why health officials are nervous about holiday gatherings.
Early research finds that Oxford and AstraZeneca’s COVID-19 vaccine is well-tolerated and produces a strong immune response in people over 70.
There are still many unknowns when it comes to the pandemic, but the early signs of success for two experimental COVID-19 vaccines make a few things clear.
Cloth mask, surgical mask, N95, bandanna: Rules on face coverings vary widely, and public health experts say standardization is needed to fight COVID-19.
As holidays approach and COVID-19 figures rise, California shows the danger of a lack of discipline and a yearning to get back to normal.
Pfizer announced more results in its ongoing COVID-19 vaccine study, which suggest that the shots are 95% effective, without serious side effects.
U.S. regulators are allowing emergency use of the first rapid coronavirus test that can be performed and developed entirely at home
Two COVID-19 vaccines might be nearing the finish line, but scientists say people still need to volunteer to help finish studying other candidates.
Coronavirus vaccines developed by Moderna and Pfizer show highly promising preliminary results in large-scale clinical testing. But key questions remain.
There’s more promising news on the COVID-19 vaccine front as Moderna says its shot provides strong protection against the coronavirus.
Medicine
A daily pill combining four cholesterol and blood pressure drugs taken with low-dose aspirin cut the risk of heart attacks, strokes and deaths by nearly a third.
-
The Supreme Court, with President Trump’s three appointees, hears arguments over whether to void the 2010 Affordable Care Act.
-
In a new study, a shot of an experimental medicine every two months worked better than daily pills at reducing women’s risk of acquiring HIV from a partner.
-
With the healthcare of 21 million people at stake, conservative justices should practice the judicial restraint they are so fond of preaching.
-
Human clinical trials are set for a drug that could prevent some of the many deaths from snakebites. The drug may also help treat COVID-19 patients.
-
Patients soon will have free electronic access to the notes their doctors write about them under a new federal requirement for transparency.
More headlines
-
Paramahansa Yogananda found in Los Angeles the perfect home base for an organization which remains a worldwide spiritual force to this day.
-
Health officials are taking a new tack in the COVID-19 fight by emphasizing research that finds a mask protects the person who wears it, not just those nearby.
-
A massive celebration after the Notre Dame-Clemson game was a potential super-spreader event, but experts say it could shed light on the coronavirus.
-
What makes some COVID-19 patients so much sicker than others? In some cases, people are more vulnerable because their immune systems are hit by friendly fire.
-
A small lab tries to alter one gene of the coronavirus, hoping that change will offer a way to kill it.
-
Developers of Sputnik V, Russia’s experimental COVID-19 vaccine, say early data suggest that it is 92% effective, but skeptics raise questions.
-
Despite strict quarantines and screening measures, Marine recruits spread the coronavirus to others even though hardly any of them had symptoms, a study found.
-
It used to be that Atlantic hurricanes would lose most of their strength within a day of making landfall. Due to climate change, that’s no longer true.
-
San Francisco has been remarkably conservative in fighting COVID-19. Will that approach keep working?
-
A winter surge of COVID-19 is now unavoidable, experts say, though its magnitude depends on what we do next. Hundreds of thousands of lives hang in the balance.
-
Brazil’s health regulator says it has halted clinical trials of China’s potential COVID-19 vaccine CoronaVac, citing an ‘adverse, serious event.’
Get our free Coronavirus Today newsletter
Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.
You may occasionally receive promotional content from the Los Angeles Times.